N-acylethanolamine (NAE)

N-acylethanolamines (NAEs) are a diverse family of endogenous bioactive lipid signaling molecules synthesized from membrane phospholipids through the action of various enzymes, most notably N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD). This class includes several prominent mediators such as anandamide (N-arachidonoylethanolamine), palmitoylethanolamide (PEA), and oleoylethanolamide (OEA). NAEs act as pleiotropic signaling molecules that regulate a wide range of physiological processes, including pain perception, inflammation, appetite regulation, and neuroprotection. They exert their biological effects by binding to and activating various receptor systems, including cannabinoid receptors (CB1 and CB2), peroxisome proliferator-activated receptor alpha (PPAR-alpha), and transient receptor potential vanilloid 1 (TRPV1). While NAEs themselves are ligands rather than therapeutic protein targets, the enzymes that regulate their levels—specifically Fatty Acid Amide Hydrolase (FAAH) and N-acylethanolamine-hydrolyzing Acid Amidase (NAAA)—are significant therapeutic targets. Drugs designed to inhibit these degradative enzymes aim to increase endogenous NAE levels to provide analgesic, anti-inflammatory, or anti-obesity effects.

Other names

N-acyl-ethanolamideN-acyl-ethanolamineNAEsFatty acid ethanolamide

N-acylethanolamines act as endogenous agonists for various receptors (CB1, CB2, PPAR-alpha, TRPV1); their signaling is modulated by drugs that inhibit degradative enzymes (FAAH, NAAA) to increase local concentrations of these lipids.